Analytical Methods & Validation Summary — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The analytical methods and their validation — the test methods used to measure identity, purity, potency, and impurities.
Why it exists. Every quality claim depends on trustworthy tests. ICH Q2 requires each analytical method to be validated (accuracy, precision, specificity, etc.) so the results that release batches are reliable.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH Q2(R2) · Q6B · Q14 (analytical procedure development)
Analytical Methods & Validation Summary — GLPI-103
| Field | Value |
|---|---|
| Document ID | M3-AMV |
| Version | 2.0 (expanded) |
| Standard | ICH Q2(R2) · Q6B · Q14 (analytical procedure development) |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]Analytical procedures and their validation supporting drug-substance and drug-product control (M3-S/M3-P), including an analytical-lifecycle (Q14) view and a worked method-transfer investigation.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Analytical Development | Initial |
| 2.0 | 2026-06-30 | Analytical Development | Expanded — validation results, ATP/Q14, system suitability, method-transfer investigation (ISS-009) |
1. Analytical Target Profile (ATP, Q14)
Each procedure was developed against a pre-defined ATP (what the method must measure and how well) using analytical QbD; method operable design regions were established for the critical chromatographic methods, supporting robustness and post-approval flexibility.
2. Methods & Validation Results (ICH Q2(R2))
| Method | Purpose | Key validated performance [MOCK] |
|---|---|---|
| RP-HPLC — assay | content | accuracy 98–102% recovery; intermediate precision RSD ≤1.5%; linear r²>0.999 (50–150%) |
| RP-HPLC — related substances | impurities | LOQ 0.05%; specificity (peak purity in forced deg.); RSD ≤5% at QL; robust to ±2 °C, ±0.1 pH, ±2% organic |
| SE-HPLC | aggregates | LOQ 0.1%; precision RSD ≤5%; resolves dimer/HMW from monomer |
| Peptide map + LC-MS/MS | identity/structure | specificity; ≥95% sequence coverage |
| Ion chromatography | acetate/TFA counter-ion | accuracy, precision, linearity |
| Karl Fischer | water | accuracy, repeatability |
| LAL (kinetic) | endotoxin | compendial validation; non-interference |
| Dissolution (oral) | release / BA surrogate | precision, robustness; discriminating for compression force |
| Cell-based bioassay | GLP-1R / APJ potency | relative potency 80–125%; intermediate precision RSD ≤10% |
3. Stability-Indicating Capability
RP-HPLC and SE-HPLC resolve all forced-degradation products (acid/base/oxidative/thermal/photolytic) from the main peak with confirmed peak purity, qualifying them as stability-indicating (M3-STAB §3).
4. System Suitability & Method Transfer — incl. Investigation ISS-009
System-suitability criteria (resolution, tailing, repeatability, signal-to-noise) are defined for each chromatographic method. During transfer of the related-substances RP-HPLC method to the QC laboratory, an out-of-expectation variability in the resolution of a critical impurity pair was observed (QA-003 ISS-009). Root-cause investigation identified column lot-to-lot selectivity variability; the transfer was re-qualified with bracketing reference standards. CAPA: a column-qualification requirement and a tightened system-suitability resolution criterion (≥1.5) were added to the method, with a designated stationary-phase chemistry — preventing recurrence. The event is a worked example of analytical lifecycle management (Q14).
Comments (0)
No comments yet. Be the first to say something!